JunionTX Completes Nearly RMB 100 Million Series A Financing to Accelerate Innovative Drug-Device Combination Platform and Product Launch

VCBeat has learned that Xiamen Junde Medical Technology Co., Ltd. (“Junde Medical”) recently completed a Series A financing round of nearly RMB 100 million. The round was led by Zhangzhou Capital Operation Group and Guoxing Investment, with participation from Pianzihuang Investment, Xiamen Haichuang Venture Capital, and Huarong Ruize Investment Management Co., Ltd. Existing shareholder Fujian Yingke Venture Capital Co., Ltd. made an additional investment, while Swap Capital served as the exclusive financial advisor. The proceeds will primarily be used for the registration, production, and sales of the company’s first oral weight-loss device, as well as to accelerate the R&D of product pipelines across its multiple core innovative drug-device combination technology platforms.

In terms of its global pipeline of innovative drug-device combination products, Junde Medical has established multiple technology platforms that are leading at both the national and global levels. The company currently has more than 10 products in development or planned for development. In addition to conducting clinical trials and regulatory registration for its first-in-China products within China, Junde Medical will also carry out clinical trials and regulatory submissions in regions such as the United States and the European Union, thereby achieving a global footprint.

Since its inception, Junde Medical has collaborated with top-tier international patent law firms to secure patents globally covering product technologies, manufacturing processes, packaging, methods of use, and new indications. To date, the company has filed over 60 patent applications worldwide, with more than 20 granted. Junde Medical will continue to actively explore collaborations with renowned experts in medicine, materials science, and bioengineering, as well as with industry-leading companies, both domestically and internationally, to provide clinicians with practical and highly effective treatment solutions.